CXCR4靶向[68Ga]Ga-PentixaFor PET/CT改善边缘区淋巴瘤分期并改变治疗管理
PentixaFor病灶检出率显著更高,导致26.8%患者分期上调、56.1%治疗管理改变;基线PentixaFor SUVmax>7.96与较低完全缓解率相关,双示踪分型可进一步区分完全缓解率。
要点
- PentixaFor对胃部及淋巴结病灶检出率显著高于FDG,靶本比更优。
- PentixaFor使26.8%患者分期上调,56.1%患者治疗管理改变。
- 双示踪分型(双阴、单阳、双阳)完全缓解率递减,可识别高危患者。
核心结论
- CXCR4靶向[68Ga]Ga-PentixaFor PET/CT在边缘区淋巴瘤初始分期中显著优于[18F]FDG,并对临床管理产生实质影响。
- 双示踪显像有潜力作为无创生物标志物用于体内表型表征,与早期治疗结局相关并识别高危患者。
研究设计与样本
- 系统评估病灶检出率、分期迁移和管理改变,并分析基线影像参数对中期治疗反应的预后价值。
主要发现
- PentixaFor病灶检出率显著高于FDG,胃部为72.0% vs. 40.0%,淋巴结为97.4% vs. 39.7%。
- PentixaFor靶本比更优,中位TBRliver为5.55 vs. 2.42(p < 0.01)。
- CXCR4靶向显像导致26.8%患者疾病分期上调(总体分期迁移29.3%),56.1%患者治疗管理改变。
- 基线PentixaFor SUVmax > 7.96与较低完全缓解率相关。
- 双示踪分型显示双阴、单阳、双阳组完全缓解率分别为100%、61.5%、36.4%。
关键数值与推荐
- PentixaFor胃部病灶检出率72.0% vs. FDG 40.0%,淋巴结97.4% vs. 39.7%。
- 中位TBRliver:PentixaFor 5.55 vs. FDG 2.42(p < 0.01)。
- 分期上调率26.8%,总体分期迁移29.3%,治疗管理改变率56.1%。
- 基线PentixaFor SUVmax > 7.96与较低完全缓解率相关。
- 双阴、单阳、双阳组完全缓解率分别为100%、61.5%、36.4%。
临床怎么用
- 对初治边缘区淋巴瘤患者,可考虑CXCR4靶向PET/CT以更准确评估全身肿瘤负荷和分期。
- 双示踪PET/CT表型分型有助于早期识别可能治疗反应不佳的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Marginal zone lymphoma (MZL) exhibits substantial clinical heterogeneity, necessitating accurate whole-body tumor burden assessment and early risk stratification. However, conventional [18F]FDG PET/CT is limited in both anatomical staging and in vivo biological characterization. This prospectively recruiting study conducted a head-to-head comparison of the CXCR4-targeted tracer [68Ga]Ga-PentixaFor and [18F]FDG in treatment-naïve patients to evaluate their complementary value in improving staging accuracy and their association with early treatment response. METHODS: Forty-one treatment-naïve MZL patients prospectively underwent dual-tracer PET/CT prior to therapy. Lesion detection rates, stage migration, and management modifications were systematically assessed. The prognostic value of baseline imaging parameters for interim treatment response was also analyzed. RESULTS: [68Ga]Ga-PentixaFor demonstrated significantly higher lesion detection rates than [18F]FDG, particularly for gastric (72.0% vs. 40.0%) and nodal involvement (97.4% vs. 39.7%), with a superior target-to-background ratio (median TBRliver: 5.55 vs. 2.42, p < 0.01). CXCR4-targeted imaging resulted in disease upstaging in 26.8% of patients (overall stage migration: 29.3%) and led to management modifications in 56.1%. Regarding therapeutic outcomes, higher baseline [68Ga]Ga-PentixaFor SUVmax (> 7.96) was associated with lower complete remission (CR) rates. Notably, dual-tracer phenotyping further demonstrated decreasing CR rates across double-negative, single-positive, and double-positive groups (100%, 61.5%, and 36.4%, respectively). CONCLUSION: [68Ga]Ga-PentixaFor PET/CT significantly outperforms [18F]FDG in initial staging of MZL and has a substantial impact on clinical management. Importantly, dual-tracer imaging shows potential as a novel, non-invasive biomarker for in vivo phenotypic characterization, which is associated with early therapeutic outcomes and the identification of high-risk patients.
引用
- Zhang Z, Hu H, Li X, et al. CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [18F]FDG. Eur J Nucl Med Mol Imaging. 2026. PMID: 42234002. doi:10.1007/s00259-026-07978-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。